Other OTC - Delayed Quote USD

Alseres Pharmaceuticals, Inc. (ALSE)

0.0050 0.0000 (0.00%)
As of October 18 at 2:06 PM EDT. Market Open.
Loading Chart for ALSE
DELL
  • Previous Close 0.0050
  • Open 0.0050
  • Bid --
  • Ask --
  • Day's Range 0.0050 - 0.0050
  • 52 Week Range 0.0050 - 0.0100
  • Volume 66
  • Avg. Volume 0
  • Market Cap (intraday) 199,127
  • Beta (5Y Monthly) 0.18
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0200
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson's disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.

www.alseres.com

--

Full Time Employees

December 31

Fiscal Year Ends

Related News

Performance Overview: ALSE

Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ALSE
50.00%
S&P 500
4.57%

1-Year Return

ALSE
50.00%
S&P 500
20.05%

3-Year Return

ALSE
99.92%
S&P 500
19.17%

5-Year Return

ALSE
99.97%
S&P 500
71.70%

Compare To: ALSE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ALSE

Valuation Measures

As of 4/19/2024
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    19.06

  • Enterprise Value/EBITDA

    -16.75

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -163.94%

  • Return on Assets (ttm)

    -247.06%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    473.73k

  • Net Income Avi to Common (ttm)

    -776.64k

  • Diluted EPS (ttm)

    -0.0200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    186.95k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -2.43M